Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

March 4, 2025

Study Completion Date

March 28, 2025

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Active Comparator CT1812

123 participants will receive a single daily dose of CT1812 (200 mg)

DRUG

Placebo Comparator

123 participants will receive a single daily dose of placebo

Trial Locations (19)

11021

Long Island Vitreoretinal Consultants, Great Neck

11735

National Ophthalmic Research Institute, Fort Myers

16507

Erie Retina Research, LLC, Erie

21204

Retina Specialists, Baltimore

27587

North Carolina Retina Associates, Wake Forest

33064

Advanced Research, Deerfield Beach

Rand Eye Institute, Deerfield Beach

33880

Center for Retina and Macular Disease, Winter Haven

37203

Tennessee Retina, PC, Nashville

76028

Star Vision Consultants, Burleson

76104

Texas Retina Associates, Fort Worth

78240

Retina Consultants of Texas, San Antonio

78750

Austin Clinical Research, LLC, Austin

85050

Phoenix Retina Associates, Phoenix

94598

Bay Area Retina Associates, Walnut Creek

95825

Retinal Consultants Medical Group, Sacramento

97401

Verum Research LLC, Eugene

02114

Ophthalmic Consultants of Boston, Boston

08820

NJ Retina, Edison

Sponsors
All Listed Sponsors
lead

Cognition Therapeutics

INDUSTRY

NCT05893537 - Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). | Biotech Hunter | Biotech Hunter